KDI tripeptide of γ1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity

Journal of Neuroscience Research

Volumn 84, Issue 3, 2006, Pages 655-665

  Väänänen, Antti J ^a   Rauhala, Pekka ^a   Tuominen, Raimo K ^a   Liesi, Päivi ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

6 OHDA; Dopaminergic neurons; KDI; Laminin; Neuronal protection; Parkinson's disease

Indexed keywords

LAMININ; LAMININ GAMMA1; LYSYLASPARTYLISOLEUCINE; OXIDOPAMINE; TRIPEPTIDE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; DOPAMINE; GLUTAMATE RECEPTOR; NEUROPROTECTIVE AGENT; NEUROTOXIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANIMAL; CELL COUNT; CELL DEATH; CELL PROTECTION; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; METABOLISM; NERVE CELL; NERVE DEGENERATION; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; CELL COUNT; CELL DEATH; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINE; LAMININ; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, GLUTAMATE; SUBSTANTIA NIGRA; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 33746933484     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20961     Document Type: Article

References (57)

1. Agid Y, Javoy F, Glowinski J, Bouvet D, Sotelo C. 1973. Injection of 6-hydrodopamine into the substantia nigra of the rat II. Diffusion and specificity. Brain Res 58:291-301.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
3. Bezard E, Gross CE, Brotchie JM. 2003. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26: 215-221.
4. Blum D, Torch S, Lambeng N, Nissou M-F, Benabid A-L, Sadoul R, Verna J-M. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
5. Chen Z-L, Strickland S. 1997. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91:917-925.
6. Chen Z-L, Indyk JA, Strickland S. 2003. The hippocampal laminin matrix is dynamic and critical for neuronal survival. Mol Biol Cell 14: 2665-2676.
7. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
8. Choi DW. 1994. Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res 100:47-51.
9. Deumens R, Blokland A, Prickaerts J. 2002. Modelling Parkinson's disease in rats: An evolution of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317.
10. Ferraz AC, Xavier LL, Hernandes S, Sulzbach M, Viola GG, Anselmo-Franci JA, Achaval M, Da Cunha C. 2003. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res 986:200-205.
11. Ferro MM, Bellissimo MI, Aselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C. 2005. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histologjcal, neurochemical, motor and memory alterations. J Neurosci Met 148:78-87.
12. Grant RJ, Clarke PBS. 2002. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia. Neuroscience 115:1281-1294.
13. Gu B, Zhang YD, Hu G. 2003. A unilateral 6-hydroxydopamine lesion decreases the expression of metabotropic glutamate receptors in rat substantia nigra. Neurosci Lett 351:186-190.
14. Hager G, Pawelzik H, Kreutzberg GW, Zieglgansberger W. 1998. A peptide derived from a neunte outgrowth-promoting domain on the gamma 1 chain of laminin modulates the electrical properties of neocortical neurons. Neuroscience 86:1145-1154.
15. Indyk JA, Chen ZL, Tsirka SE, Strickland S. 2003. Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury. Neuroscience 116:359-371.
16. Javoy F, Sotelo C, Herbet A, Agid Y. 1976. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res 102:201-215.
17. Kearns CM, Gash DM. 1995. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111.
18. Keller G. 2005. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 19:1129-1155.
19. Liebkind R, Laatikainen T, Liesi P. 2003. Is the soluble KDI domain of gamma1 laminin a regeneration factor for the mammalian central nervous system? J Neurosci Res 73:637-643.
20. Liesi P, Kaakkola S, Dahl D, Vaheri A. 1984. Laminin is induced in astrocytes of adult brain by injury. EMBO J 3:683-686.
21. Liesi P. 1985a. Do neurons in the vertebrate CNS migrate on laminin? EMBOJ 4:1163-1170.
22. Liesi P. 1985b. Laminin-immunoreactive glia distinguish regenerative adult CNS systems from non-regenerative ones. EMBO J 4:2505-2511.
23. Liesi P, Silver J. 1988. Is glial laminin involved in axon guidance in the mammalian CNS? Dev Biol 130:774-785.
24. Liesi P, Närvänen A, Soos J, Sariola H, Snounou G. 1989. Identification of a neurite outgrowth promoting domain of laminin using synthetic peptides. FEBS Lett 244:141-148.
25. Liesi P. 1990. Extracellular matrix and neuronal movement. Experientia 46:900-907.
26. Liesi P, Hager G, Dodt HU, Seppälä I, Zieglgansberger W. 1995. Domain-specific antibodies against the B2 chain of laminin inhibit neuronal migration in the neonatal rat cerebellum. J Neurosci Res 40:199-206.
27. Liesi P, Laatikainen T, Wright JM. 2001a. A biologically active sequence (KDI) mediates the neurite outgrowth function of the gamma1 chain of laminin-1. J Neurosci Res 66:1046-1053.
28. Liesi P, Fried G, Stewart R. 2001b. Neurons and glial cells of the embryonic human brain and spinal cord express multiple and distinct isoforms of laminin. J Neurosci Res 64:144-167.
29. Liesi P, Kauppila T. 2002. Induction of type IV collagen and other basement membrane associated proteins after spinal cord injury of the adult rat may participate in formation of the glial scar. Exp Neurol 173:31-45.
30. Lindvall O, Björklund A. 2004. Cell therapy in Parkinson's disease. NeuroRx 1:382-393.
31. Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med 330:613-622.
32. Luckenbill-Edds L. 1997. Laminin and the mechanism of neuronal out-growth. Brain Res Brain Res Rev 23:1-27.
33. Matsuzawa M, Weight F, Potember R, Liesi P. 1996. Directional neurite outgrowth and axonal differentiation of embryonic hippocampal neurons are induced by a neurite outgrowth domain of the B2 chain of laminin. Int J Dev Neurosci 14:283-295.
34. Matsuzawa M, Tokumitsu S, Knoll W, Liesi P. 1998. Molecular gradient along the axon pathway is not required for directional axon growth. J Neurosci Res 53:114-124.
35. Mattson MP. 2003. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 3:65-95.
36. Mercuri NB, Bernardi G. 2005. The 'magic' of 1-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 26:341-344.
37. Mishra RK, Marshall AM, Varmuza SL. 1980. Supersensitivity in rat caudate nucleus: Effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res 200:47-57.
38. Morgan C, Inestrosa NC. 2001. Interactions of laminin with the amyloid beta peptide. Implications for Alzheimer's disease. Braz J Med Biol Res 34:597-601.
39. Murtomäki S, Risteli J, Risteli L, Koivisto UM, Johansson S, Liesi P. 1992. Laminin and its neurite outgrowth-promoting domain in the brain in Alzheimer's disease and Down's syndrome patients. J Neurosci Res 32:261-273.
40. Möykkynen T, Liebkind R, Sjöberg J, Korpi ER, Liesi P. 2005. The neuroprotective KDI domain of gamma1-laminin is a universal and potent inhibitor of ionotropic glutamate receptors. J Neurosci Res 81: 797-804.
41. Nagai N, Urano T, Endo A, Takahashi H, Takada Y, Takada A. 1999. Neuronal degeneration and a decrease in laminin-like immunoreactivity is associated with elevated tissue-type plasminogen activator in the rat hippocampus after kainic acid injection. Neurosci Res 33:147-154.
42. Palu E, Liesi P. 2002. Differential distribution of laminins in Alzheimer's and normal brain tissues. J Neurosci Res 69:243-256.
43. Parkinson JA. 1817. An essay on the shaking palsy. London, UK: Sherwood, Neely, and Jones.
44. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
45. Sattler R, Tymianski M. 2001. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 24: 107-129.
46. Schober A. 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224.
47. Schwarting RKW, Huston JP. 1996. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215-266.
48. Shaw G, Osborn M, Weber K. 1981. An immunofluorescence microscopical study of the neurofilament triplet proteins, vimentin and glial fibrillary acidic protein within the adult rat brain. Eur J Cell Biol 26: 68-82.
49. Shetty AK, Turner DA. 1995. Non-phosphorylated neurofilament protein immunoreactivity in adult and developing rat hippocampus: specificity and application in grafting studies. Brain Res 676:293-306.
50. Stanic D, Finkelstein DI, Bourke DW, Drago J, Horne MK. 2003. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 18:1175-1188.
51. Tatard VM, Menei P, Benoit JP, Montero-Menei CN. 2005. Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach. Curr Drug Targets 6:81-96.
52. Twelves D, Perkins KSM, Counsell C. 2003. Systematic review of incidence studies of Parkinson's disease. Move Disord 18:19-31.
53. Ungerstedt U. 1968. 6-Hydroxy-dopamine induced degeneration of central dopamine neurons. Eur J Pharmacol 5:107-110.
54. Väänänen AJ, Libkind R, Kankuri E, Liesi P, Rauhala P. 2004. Angeli's salt and spinal motor neuron injury. Free Radic Res 38:271-281.
55. Wiksten M, Liebkind R, Laatikainen T, Liesi P. 2003. Gamma1 laminin and its biologically active KDI-domain may guide axons in the floor plate of the embryonic human spinal cord. J Neurosci Res 71:338-352.
56. Wiksten M, Väänänen AJ, Liebkind R, Liesi P. 2004a. Regeneration of adult spinal cord is promoted by the soluble KDI-domain of gamma1 laminin. J Neurosci Res 78:403-410.
57. Wiksten M, Väänänen AJ, Liebkind R, Rauhala P, Liesi P. 2004b. The soluble KDI-domain of gamma1 laminin protects adult rat hippocampus from excitotoxicity of kainic acid. J Neurosci Res 78:411-419.